Beximco Pharma Granted Sub-license To Produce Molupiravir - Quick Facts

Beximco Pharmaceuticals Limited (BXP.L) said the United Nations-backed Medicines Patent Pool has expanded its network of partnered generic manufacturers to include Beximco Pharma. Under the partnership, the company will be granted a sub-license by the MPP to produce molnupiravir, an oral drug for the treatment of COVID-19. Molnupiravir is an oral antiviral to treat symptomatic COVID-19. Beximco Pharma will manufacture molnupiravir in Bangladesh and expects to start domestic distribution and export from the end of 2022.

The sub-license deal is a result of the licensing agreement signed by the MPP and MSD in October 2021 to facilitate affordable global access for molnupiravir, which MSD is developing in partnership with Ridgeback Biotherapeutics.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Teva Pharmaceuticals USA, Inc. has recalled one lot of platelet-reducing drug Anagrelide in the form of capsules due to dissolution test failure detected during routine stability testing, the U.S. Food and Drug Administration, or FDA, said in a statement. The U.S. Food and Drug Administration said it has taken steps to make available millions of cans of additional infant and specialty formula to U.S. consumers in the coming months. Under the agency's recent increased flexibilities, British nutrition products maker Kendal Nutricare will send about 2 million cans of infant formula under the Kendamil brand initially to U.S. beginning in June. Video streaming giant Netflix Inc. announced the availability of a variety of mobile games. Players can download the games directly from the Netflix mobile app. The new games include Dragon Up (East Side Games), Moonlighter (11 Bit Studios), Townsmen - A Kingdom Rebuilt (HandyGames), and Exploding Kittens - The Game (Exploding Kittens Digital).
Follow RTT